Two experimental drugs that target amylin helped adults lose weight when tested on their own. Petrelintide and eloralintide each lowered average weight compared with placebo in a separate Phase 2 study. For people wondering whether a drug that works differently from GLP-1 medicines might also be easier to take, the early trials offer a much narrower answer.
A November 19 review of emerging obesity-drug targets puts amylin among several routes researchers are exploring. Its references include a May 2026 analysis that looked at eloralintide and other amylin-based therapies. The original eloralintide study and a newer petrelintide paper, published online in September, help answer one part of the review’s much broader question: how much evidence do we have that an amylin drug can reduce weight by itself?
What “amylin-only” means
Amylin is released after eating and helps regulate appetite. Petrelintide acts like human amylin, and eloralintide acts on amylin receptors. The active groups in the two trials received one of those study drugs as a weekly injection, without an added GLP-1 drug. That differs from CagriSema, which pairs the amylin analogue cagrilintide with the GLP-1 drug semaglutide. The standalone trials isolate the effect of each study drug against its own placebo.
What each drug did against placebo
The ZUPREME 1 study randomly assigned 493 adults, of whom 485 received at least one dose. It enrolled adults with obesity or with overweight plus high blood pressure or abnormal blood lipids, and excluded people with type 2 diabetes. At week 28, the main measurement point, average weight fell by an estimated 7.9% to 9.8% across the petrelintide groups and 1.7% with placebo in the paper’s efficacy analysis. The study continued through 42 weeks. The registry describes petrelintide and placebo as additions to a reduced-calorie diet and increased physical activity.
The eloralintide study randomly assigned 263 adults with obesity or with overweight plus a weight-related condition. It also excluded people with type 2 diabetes. The efficacy analysis estimated average weight reductions of about 9% to 20% across six eloralintide regimens and 0.4% with placebo at week 48, its primary endpoint. Each range describes different regimens within one trial. It describes neither the range of individual outcomes nor a dose recommendation.
The two papers report efficacy estimands, which define the treatment effect the researchers set out to estimate under the study’s assumptions. These model-based averages leave open what might happen among all starters in ordinary care, where some people miss doses or stop taking a medicine. The trials also measured their main outcomes 20 weeks apart. Neither trial assigned participants to a GLP-1 group or tested the two amylin drugs against each other.
What the nausea numbers leave open
In the petrelintide study, 20% of participants across the active groups reported nausea, compared with 6% on placebo. In the eloralintide study, the proportion ranged from 11% to 64% across individual active regimens, compared with 14% on placebo. One report pools the active groups for this figure and the other breaks them out. The placebo rates also differ. A headline that picks one number from each paper can make one drug look easier to tolerate without a study that directly answers that question.
How long did symptoms last, and how often did they lead people to stop treatment? Those questions matter when a medicine is being developed for long-term use. These studies are also too small to settle questions about uncommon harms.
What to look for in Phase 3
ZUPREME-3 and ENLIGHTEN-1 are recruiting for separate Phase 3 comparisons with placebo. Both list a primary weight measurement at week 64. The registry entries describe what the studies will measure, and neither had posted results when checked. When results come out, check how much of the weight change persists over that longer period and how the analysis handles people who stop. Our guide to reading weight-loss trials walks through those questions. Both drugs are investigational for weight management in the United States, according to the available trial records and a check of the FDA approval database.



